

AxoGen, Inc.  
Form SC 13G/A  
February 06, 2015  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)\***

AxoGen, Inc.

(Name of Issuer)

Common Stock, par value \$0.01 per share

(Title of Class of Securities)

523251 10 6

(CUSIP Number)

December 22, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to \*the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see the Notes*).

---

CUSIP No. 523251 10 6 13G Page 2 of 6 Pages

Names of  
Reporting  
Persons

1. PDL  
BioPharma,  
Inc.

Check  
the  
Appropriate  
Box  
if

2. a  
Member  
of  
a  
Group  
(see  
instructions)

(a)  
(b)  
SEC USE

3. ONLY

Citizenship  
or Place of  
4. Organization

Delaware

Number of		Sole Voting
Shares	5.	Power
		643,382

Beneficially	6.	Shared
Owned by		Voting
		Power

Each	0
Reporting Person With:	Sole Dispositive Power
7.	643,382
	Shared Dispositive Power
8.	0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 643,382
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares  (see instructions)
11.	Percent of Class Represented by Amount in Row 9 3.30%
12.	Type of Reporting Person (see instructions) CO



CUSIP No. 523251 10 6 13G Page 3 of 6 Pages

Name of Issuer:

**Item 1(a).** AxoGen, Inc.

Address of Issuer's Principal Executive Offices:

**Item 1(b).** 13631 Progress Blvd., Suite 400 Alachua, Florida 32615

Name of Person Filing:

**Item 2(a).** PDL BioPharma, Inc.

Address of Principal Business Office or, if none, Residence:

**Item 2(b).** 932 Southwood Boulevard, Incline Village, Nevada 89451

Citizenship:

**Item 2(c).** Delaware

Title of Class of Securities:

**Item 2(d).** Common Stock, par value \$0.01 per share

CUSIP Number:

**Item 2(e).** 523251 10 6

**Item 3.** If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

Edgar Filing: AxoGen, Inc. - Form SC 13G/A

- (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

\_\_\_\_\_

CUSIP No. 523251 10 6 13G Page 4 of 6 Pages

#### Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount Beneficially Owned: 643,382
- (b) Percent of Class: 3.30%
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote 643,382
- (ii) Shared power to vote or to direct the vote 0
- (iii) Sole power to dispose or to direct the disposition of 643,382
- (iv) Shared power to dispose or to direct the disposition of 0

*Instruction:* For computations regarding securities which represent a right to acquire an underlying security *see* §240.13d-3(d)(1).

#### Item 5. Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following:

*Instruction:* Dissolution of a group requires a response to this item.

#### Item 6. Ownership of More than 5 Percent on Behalf of Another Person

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.



Not applicable.

**Item Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By  
7. the Parent Holding Company or Control Person.**

If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

Not applicable.

---

CUSIP No. 523251 10 6 13G Page 5 of 6 Pages

**Item 8. Identification and Classification of Members of the Group**

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

Not applicable.

**Item 9. Notice of Dissolution of a Group**

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. *See* Item 5.

Not applicable.

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 523251 10 6 13G Page 6 of 6 Pages

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date February 6, 2015

**PDL BioPharma, Inc.**

By: /s/ John P. McLaughlin  
Name: John P. McLaughlin  
Title: President and Chief  
Executive Officer